A5029796262- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Hair Growth and Disorders
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Autoimmune Bullous Skin Diseases
- Monoclonal and Polyclonal Antibodies Research
- Dermatology and Skin Diseases
- Pharmacological Effects of Natural Compounds
- Wound Healing and Treatments
- Biomedical Ethics and Regulation
- T-cell and B-cell Immunology
- Spondyloarthritis Studies and Treatments
- Peripheral Neuropathies and Disorders
- Toxin Mechanisms and Immunotoxins
- Autoimmune and Inflammatory Disorders
- RNA regulation and disease
- Colorectal Cancer Treatments and Studies
- Cutaneous lymphoproliferative disorders research
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Inflammatory mediators and NSAID effects
- Chemokine receptors and signaling
Pfizer (United States)
2014-2025
Ibero American University
2016
Newcastle upon Tyne Hospital
2013
Newcastle University
2013
Albany Medical Center Hospital
2013
Stanford University
2013
Metroplex Clinical Research Center
2013
Hospital Universitario La Paz
2013
Cabrini Hospital
2013
Peking University People's Hospital
2013
Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that being investigated as targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis.In this phase 3, double-blind, placebo-controlled, parallel-group, 6-month study, 611 patients were randomly assigned, in 4:4:1:1 ratio, to 5 mg of tofacitinib twice daily, 10 placebo 3 months followed by or daily. The primary end points, assessed at month the percentage with least 20% improvement American College...
Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that being investigated for the treatment of rheumatoid arthritis.In this 12-month, phase 3 trial, 717 patients who were receiving stable doses methotrexate randomly assigned to 5 mg tofacitinib twice daily, 10 40 adalimumab once every 2 weeks, or placebo. At month 3, in placebo group did not have 20% reduction from baseline number swollen and tender joints switched blinded fashion either daily; at 6, all still fashion. The...
Methotrexate is the most frequently used first-line antirheumatic drug. We report findings of a phase 3 study monotherapy with tofacitinib, an oral Janus kinase inhibitor, as compared methotrexate in patients rheumatoid arthritis who had not previously received or therapeutic doses methotrexate.We randomly assigned 958 to receive 5 mg 10 tofacitinib twice daily at dose that was incrementally increased 20 per week over 8 weeks; 956 The coprimary end points month 6 were mean change from...
Abstract Objective The purpose of this 24‐month phase III study was to examine structural preservation with tofacitinib in patients rheumatoid arthritis (RA) an inadequate response methotrexate (MTX). Data from a planned 12‐month interim analysis are reported. Methods In double‐blind, parallel‐group, placebo‐controlled study, receiving background MTX were randomized 4:4:1:1 at 5 mg twice daily, 10 placebo and daily. At month 3, nonresponder placebo‐treated advanced blinded manner receive as...
Abstract Objective To determine the efficacy, safety, and tolerability of 3 different dosages CP‐690,550, a potent, orally active JAK inhibitor, in patients with rheumatoid arthritis (RA) whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate toxic response. Methods Patients (n = 264) were randomized equally to receive placebo, 5 mg 15 30 CP‐690,550 twice daily for 6 weeks, followed up additional weeks after treatment. The primary efficacy end point was American...
Chinese translation Background: Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses disease-modifying antirheumatic drugs (DMARDs). Tofacitinib is a novel, oral, Janus kinase inhibitor that treats RA. Objective: To evaluate the efficacy safety of tofacitinib in combination nonbiologic DMARDs. Design: 1-year, double-blind, randomized trial (ClinicalTrials.gov: NCT00856544). Setting: 114 centers 19 countries. Patients: 792 active RA despite DMARD therapy....
To compare the efficacy, safety, and tolerability of 5 doses oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for treatment active rheumatoid arthritis (RA) in patients an inadequate response to disease-modifying antirheumatic drugs.In this 24-week, double-blind, phase IIb study, RA (n = 384) were randomized receive placebo, at 1, 3, 5, 10, 15 mg administered orally twice a day, 40 injected subcutaneously every 2 weeks (total 6 injections) followed by day 12 weeks. The...
Abstract Objective To compare the efficacy, safety, and tolerability of 6 dosages oral tofacitinib (CP‐690,550) with placebo for treatment active rheumatoid arthritis (RA) in patients receiving a stable background regimen methotrexate (MTX) who have an inadequate response to MTX monotherapy. Methods In this 24‐week, double‐blind, phase IIb study, RA (n = 507) were randomized receive or (20 mg/day, 1 mg twice daily, 3 5 10 15 daily). All continued dosage MTX. The primary end point was...
To compare the efficacy, safety, and tolerability of 4 doses oral tofacitinib (CP-690,550) with placebo in Japanese patients active rheumatoid arthritis (RA) receiving stable background methotrexate (MTX) who had an inadequate response to MTX alone.A total 140 were randomized receive 1, 3, 5, 10 mg twice a day or this 12-week, phase II, double-blind study. All remained on MTX. Efficacy safety assessed at weeks 2, 4, 8, 12. The primary efficacy end point was American College Rheumatology 20%...
The pharmaceutical industry continues to face significant challenges. Very few compounds that enter development reach the marketplace, and investment required for each success can surpass $1.8 billion. Despite attempts improve efficiency increase productivity, total rise whereas output of new medicines declines. With costs increasing exponentially through phase, it is failure in phase II III most wasteful. In today's paradigm, late-stage principally a result insufficient efficacy. This...
The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged 12 years with alopecia areata (AA). objective this study was to evaluate the safety ritlecitinib integrated analysis four AA. Two cohorts were analyzed: a placebo-controlled all-exposure cohort. Proportions size–adjusted incidence rates (IRs) adverse events (AEs) interest laboratory abnormalities are reported. In cohort (n = 881;...
Objective Although total joint arthroplasty (TJA) is a common procedure and an important outcome in rheumatoid arthritis (RA), little known about its prevalence, failure rate, or predictors over the course of illness. The current study evaluated these factors 1,600 consecutive RA patients seen during period observation that extended 23 years. Methods Beginning 1974, data from 34,040 patient visits were entered prospectively into computer databank. Data consisted laboratory, radiographic,...
Objectives: To determine the efficacy of CP-690,550 in improving pain, function and health status patients with moderate to severe active rheumatoid arthritis (RA) an inadequate response methotrexate or a tumour necrosis factor α inhibitor. Methods: Patients were randomised equally placebo, 5, 15 30 mg twice daily for 6 weeks, weeks’ follow-up. The patient’s assessment pain (pain), disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) Short Form-36 (SF-36) recorded....
CP-690550 is a small molecule inhibitor of Janus kinase 3 (JAK3), critical enzyme in the signaling pathway multiple cytokines (interleukin (IL)-2, -7, -15 and -21) that are important various T cell functions including development, activation homeostasis. The purpose this study was to evaluate murine collagen-induced (CIA) rat adjuvant-induced (AA) models rheumatoid arthritis (RA).CIA AA were induced using standard protocols animals received JAK3 via osmotic mini-pump infusion at doses...
Objectives. To evaluate oral tofacitinib versus placebo for treatment of active rheumatoid arthritis in Japanese patients with inadequate response to disease-modifying antirheumatic drugs. Methods. In this double-blind, placebo-controlled, randomized, parallel-group, 12-week, phase 2 study (clinicaltrials.gov NCT00687193), 317 received tofacitinib: 1, 3, 5, 10, or 15 mg as monotherapy twice daily (BID). Primary endpoint: rate by American College Rheumatology (ACR) ≥ 20% improvement criteria...
<h3>Objectives</h3> To evaluate the efficacy and safety of atorvastatin versus placebo in modifying lipids patients with rheumatoid arthritis (RA) receiving oral Janus kinase inhibitor, tofacitinib. <h3>Methods</h3> A randomised, controlled, multicentre phase 2 study, open-label for tofacitinib blinded atorvastatin. Patients received 10 mg twice daily 12 weeks; at week 6, were randomly assigned 1:1 to receive once or 6 weeks. Main outcome measures lipid moieties, American College...
This subgroup analysis of the ALLEGRO phase 2b/3 trial (NCT03732807) evaluated efficacy and safety ritlecitinib, an oral, selective dual JAK3/TEC family kinase inhibitor, for treatment alopecia areata (AA) in patients aged 12-17 years.In ALLEGRO-2b/3, ≥12 years with AA ≥50% scalp hair loss received once-daily ritlecitinib 50 or 30 mg (±4-week 200-mg loading dose) 10 placebo 24 weeks. In a subsequent 24-week extension period, groups continued their doses, initially assigned to switched 200/50...
The long-term treatment of rheumatoid arthritis (RA) most often involves a sequence different therapies. response to therapy, disease progression and detailed knowledge the role therapies along pathways are key aspects help physicians identify best strategy. Thus, understanding effectiveness therapeutic sequences is particular importance in evaluation RA strategies. objective this study was systematically review quantitatively evaluate relationship between clinical biologic treatments number...